Yunhao Tan, Kenta Mosallanejad, Qingxiu Zhang, Stephen O'Brien, Meghan Clements, Stuart Perper, Sarah Wilson, Sudiksha Chaulagain, Jing Wang, Mary Abdalla, Helen Al-Saidi, Danyal Butt, Anca Clabbers, Kwasi Ofori, Beth Dillon, Bohdan Harvey, John Memmott, Christopher Negron, David Winarta, Catherine Tan, Amlan Biswas, Feng Dong, Vanessa Morales-Tirado, Xiaoqing Lu, Gurminder Singh, Michael White, Shanna Ashley, Heather Knight, Susan Westmoreland, Lucy Phillips, Tracy Carr, Lauren Reinke-Breen, Rajeeva Singh, Jianwen Xu, Kan Wu, Lisa Rinaldi, Brian Stoll, Yupeng David He, Lisa Hazelwood, Jozsef Karman, Andrew McCluskey, William Stine, Ivan Correia, Stephen Gauld, Marc C Levesque, Geertruida Veldman, Cedric Hubeau, Timothy Radstake, Ramkrishna Sadhukhan, Edda Fiebiger
Fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF) and systemic scleroderma (SSc), are commonly associated with high morbidity and mortality, thereby representing a significant unmet medical need. Interleukin 11 (IL11)-mediated cell activation has been identified as a central mechanism for promoting fibrosis downstream of TGFβ. IL11 signaling has recently been reported to promote fibroblast-to-myofibroblast transition, thus leading to various pro-fibrotic phenotypic changes. We confirmed increased mRNA expression of IL11 and IL11Rα in fibrotic diseases by OMICs approaches and in situ hybridization...
2024: Frontiers in Immunology